Literature DB >> 6206017

Studies on the role of sex-hormone-binding globulin (SHBG) in benign prostatic hypertrophy in men. I. Clinical research.

A Pachman.   

Abstract

The effect of testosterone concentration and the sex-hormone-binding globulin (SHBG) binding capacity were studied in the blood of young men (19-35 years), older men (54-74 years) and in patients with hypertrophy of the prostate gland. In addition, the behaviour of these parameters after removal of the hypertrophic prostate gland was determined in the early postoperative period. It was found that the serum testosterone concentration falls with age. The lowest concentration was noted in patients with prostatic hypertrophy. It was also found that the SHBG testosterone binding capacity was greater in the sera of older men and of prostatic hypertrophy patients. Testosterone concentration did not change significantly after removal of the hypertrophic prostate; there was, however, a decrease in the SHBG binding capacity. The authors put forward the hypothesis that increased SHBG binding capacity may be a defense mechanism of the organism in cases of prostatic hypertrophy. By restricting the passage of testosterone into the cell, SHBG lowers the metabolism of this androgen in the target tissue and so prevents its further growth.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206017     DOI: 10.1007/bf02082778

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  23 in total

1.  Steroid-protein interactions.

Authors:  W H DAUGHADAY
Journal:  Physiol Rev       Date:  1959-10       Impact factor: 37.312

2.  Androgen metabolism in human prostatic tissue.

Authors:  R Hampl; S Röhling; R Petrík; L Stárka
Journal:  Endocrinol Exp       Date:  1972

3.  The steroid binding beta-globulin in plasma: pathophysiological data.

Authors:  P De Moor; O Steeno; W Heyns; H Van Baelen
Journal:  Ann Endocrinol (Paris)       Date:  1969       Impact factor: 2.478

4.  [Physiopathology and treatment of hormonal disorders in prostatic hyperplasia].

Authors:  B Baranowska
Journal:  Endokrynol Pol       Date:  1978 Nov-Dec       Impact factor: 1.582

5.  [Serum testosterone level and excretion of androgen metabolites in patients with hypertrophy of the prostatic gland].

Authors:  B Baranowska; B Migdalska; J Szymanowski; I Kozlowicz
Journal:  Endokrynol Pol       Date:  1977       Impact factor: 1.582

6.  Correlation among prostate stroma, plasma estrogen levels, and urinary estrogen excretion in patients with benign prostatic hypertrophy.

Authors:  U Seppelt
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

7.  Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man.

Authors:  P K Siiteri; J D Wilson
Journal:  J Clin Invest       Date:  1970-09       Impact factor: 14.808

8.  In vivo uptake and metabolism of 3H-testosterone and 3H-5 -dihydrotestosterone by human benign prostatic hypertrophy.

Authors:  H Becker; J Kaufmann; H Klosterhalfen; K D Voigt
Journal:  Acta Endocrinol (Copenh)       Date:  1972-11

9.  [Metabolism of 3H-testosteron and 3H-5alpha-DHT in the normal and adenomatous prostate (author's transl)].

Authors:  H Becker; H Klosterhalfen; K D Voigt
Journal:  Urol Int       Date:  1973       Impact factor: 2.089

10.  Serum hormone levels in benign prostatic hyperplasia.

Authors:  H Sköldefors; B Blomstedt; K Carlström
Journal:  Scand J Urol Nephrol       Date:  1978
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.